Silintan capsules are recalled after the Food and Drug Administration found they were tainted with another drug.
MedPage Today on MSN
FDA Moves to 'Get Out of the Way' of Wearables, AI in the Clinic
Torous noted that over the summer, a company called WHOOP received an FDA warning letter over a product that could measure ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
Moving Biotech receives US FDA’s IND clearance for 4P004; strengthens its position as a leading innovator in disease-modifying osteoarthritis therapeutics: Lille, France Saturd ...
Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...
VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback